secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001628280-22-031808
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon Pharmaceuticals to merge with GRI Bio in reverse merger; GRI shareholders to own 83-96.7% of combined company
--------------------------------------------------------------------------------

- Reverse merger: Vallon Merger Sub merges into GRI; GRI survives as wholly owned subsidiary of Vallon.
- Post-closing, GRI shareholders expected to own 83.0% to 96.7% of Vallon; Marc Hertz (GRI CEO) to become CEO.
- Pre-merger financing: $3.3M bridge notes (Altium) convertible to ~$2.5M cash; $12.25M equity investment at close.
- Lock-up agreements for 90 days after earliest of Rule 144 eligibility or one-year anniversary; termination fee $2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/0001628280-22-031808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/val-20221213.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-031808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer